Log In

 

Company Name : Takeda Pharmaceutical Company Limited

Wednesday, January 24, 2018 12:20PM IST (6:50AM GMT)

(BW)(TAKEDA-PHARMACEUTICAL)

Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year


Osaka, Japan

Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights as one of the 2018 Global 100 Most Sustainable Corporations in the World (Global 100) for the third consecutive year. This distinction is based on 17 key performance indicators including financial management, clean revenue, and supplier performance. Takeda performed in the top 25% on innovation capacity, receiving notable recognition for its leadership diversity. Global 100 companies in 2018 represent the top 1.3% in the world on sustainability performance. The Index launched in 2005; results are disclosed annually at the World Economic Forum in Davos.

 

As a LEAD company within the United Nations Global Compact, Takeda’s established track record in sustainability is guided by long-term international targets such as the Sustainable Development Goals (SDGs). Takeda is the only Japanese pharmaceutical company and among the four companies from Japan to make the final 100 in 2018, and one of just ten pharmaceutical companies in the world to be listed.

 

“Takeda is honored to be recognized once again for our commitment to sustainability, particularly alongside such distinguished global corporations,” said Haruhiko Hirate, Corporate Communications & Public Affairs Officer. “We strive to create and maximize long-term economic, social, and environmental value worldwide, led by our unique and diverse corporate governance, through our corporate social responsibility (CSR), which contributes to the lasting health of patients worldwide through long-term investments in disease prevention, capacity building, and access to healthcare. As a company, Takeda strives for Better Health and a Brighter Future for people worldwide through leading innovation in medicine, together with the global community.”

 

In addition to the Global 100 Index, Takeda is recognized by multiple Socially Responsible Investment (SRI) valuations.
 

Name of Index/Investment
Universe/Ratings

 

Company/
Organization Conducting
Assessment

  Country   Honors Awarded
Dow Jones Sustainability Asia Pacific Index   S&P Dow Jones Indices   US   8th consecutive year
FTSE4Good Global Index   FTSE Russel   UK   13th consecutive year
Ethibel EXCELLENCE Investment Register   Forum Ethibel   BEL   three times
Prime Status   Oekom   GER   first time
 

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited (TOKYO:4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.

 

Additional information about Takeda is available through its Sustainable Value Report, https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/.

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Media Contacts:
Japanese Media
Takeda Pharmaceutical Company Limited
Satoko Imai, +81-3-3278-2037
satoko.imai@takeda.com


More News from Takeda Pharmaceutical Company Limited

31/07/2018 6:15PM

Takeda Reports First Quarter FY2018 Results

Strong start on underlying revenue and profitability led by Growth Drivers and Opex discipline Reported operating profit and EPS impacted by large transactions in Q1 FY2017: 106.3 billion yen one-time gain on the ...

25/07/2018 6:22PM

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the global, randomized, Phase 3 ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1stLine) trial met its primary endpoint at the first pre-specified ...

19/07/2018 2:23PM

New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis

Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced top-line results from the VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) ...

Similar News

14/08/2018 2:15PM Image

First University Based Tabletop Accelerator in the Country Becomes Functional at Manipal Academy of Higher Education, Manipal

An indigenously designed and fabricated Tabletop Accelerator (TTA) delivered the first beam on target today at the Manipal Centre for Natural Sciences, Manipal Academy of Higher Education, Manipal. Designed by IUAC, New ...

No Image

14/08/2018 11:30AM Image

#MissionMillion2018 – Building a Hunger-Free India This Independence Day

Hunger is more than missing a meal. Hunger is a crisis that has almost a billion people in its grip. 11.3% of the world’s population is hungry. At the same time 1/3rd of the world’s produce goes to waste. So, where does ...